Conduct Phase II/III clinical trials to evaluate the efficacy of a ravidasvir + sofosbuvir combination
current phase of drug development
updated 29 Feb 2020
Hepatitis C is one of a very few diseases which could be eliminated globally with the tools that exist today, provided there is a political will to do so. WHO has a goal to eliminate viral hepatitis as a major public health threat by 2030, yet, today, more people get infected by hepatitis C than get treated every year.
Although new safe and highly efficacious direct-acting antivirals (DAAs) have been available for several years, access to affordable hepatitis C treatment remains extremely limited in many developing countries. Securing wider access to DAAs will be necessary to develop a public health approach to the disease and put this growing epidemic into reverse.
Ravidasvir was developed by the US biopharmaceutical company Presidio Pharmaceuticals and identified by DNDi. In 2016, Presidio Pharmaceuticals, DNDi, and the Egyptian generic manufacturer Pharco Pharmaceuticals signed a licence agreement to secure supplies of ravidasvir and of sofosbuvir. In 2016, DNDi launched a Phase II/III study in Malaysia and Thailand to assess the efficacy, safety, tolerability, pharmacokinetics, and acceptability of 12- and 24-week regimens containing the drug candidate ravidasvir, in combination with sofosbuvir, for people living with hepatitis C.
DNDi and The Foundation for Innovative New Diagnostics (FIND) also partner on a project in collaboration with the Ministry of Health in Malaysia to generate evidence to support policy change and scale up of hepatitis C diagnosis and treatment.
News & publications
- Find the Missing Millions: Malaysia’s experience with nationwide hepatitis C screening campaign in the general population. Journal of Viral Hepatitis, January 2020.
- Comment on: “Projections of the Healthcare Costs and Disease Burden due to Hepatitis C Infection Under Different Treatment Policies in Malaysia, 2018–2040”. Applied Health Economics and Health Policy, December 2019.
- 25 November 2019 – Efforts to register new hepatitis C treatment in Malaysia receive support from Pharmaniaga
- 23 July 2018 – FIND and DNDi team up to support Malaysian MOH efforts to simplify and decentralize hepatitis C screening & treatment
- Initial results presented at the International Liver Congress 2018
- 12 April 2018 – New affordable hepatitis C combination treatment shows 97% cure rate
- 5 March 2018 – Pharmaceutical companies and non-profits team up to provide affordable hepatitis C treatment in Latin America
- 13 April 2016 – Drugs for Neglected Diseases initiative and Pharco Pharmaceuticals to test affordable hepatitis C regimen with support of Malaysian and Thai governments
Get our latest news, personal stories, research articles, and job opportunities.